Pharmaceuticals in Scandinavia
Pharmaceuticals in Scandinavia
SUMMARY
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Scandinavian pharmaceuticals market had total revenues of $14,292.7m in 2019, representing a compound annual growth rate (CAGR) of 4.8% between 2015 and 2019.
- Nordic Life Sciences clusters are strongly associated with geographical areas close to the capital cities of Sweden (Stockholm), Denmark (Copenhagen), Norway (Oslo), and Finland (Helsinki).
- The Nordic market is attractive from a number of perspectives: high degree of education, well-known researchers, good infrastructure, high innovation rate and established data registries.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Scandinavia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts
- What was the size of the Scandinavia pharmaceuticals market by value in 2019?
- What will be the size of the Scandinavia pharmaceuticals market in 2024?
- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in Scandinavia's pharmaceuticals market?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Market share
7.2. Who are the leading players?
7.3. What are the strengths/weaknesses of leading players?
7.4. What strategies do leading players follow?
7.5. Are there any threats towards leading players?
8 COMPANY PROFILES
8.1. Novartis AG
8.2. Sanofi SA
8.3. F. Hoffmann-La Roche Ltd
8.4. Pfizer Inc.
9 APPENDIX
9.1. Methodology
9.2. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Market share
7.2. Who are the leading players?
7.3. What are the strengths/weaknesses of leading players?
7.4. What strategies do leading players follow?
7.5. Are there any threats towards leading players?
8 COMPANY PROFILES
8.1. Novartis AG
8.2. Sanofi SA
8.3. F. Hoffmann-La Roche Ltd
8.4. Pfizer Inc.
9 APPENDIX
9.1. Methodology
9.2. About MarketLine
LIST OF TABLES
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2015-19
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2019
Table 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2019-24
Table 4: Scandinavia pharmaceuticals market share: % share, by value, 2019
Table 5: Novartis AG: key facts
Table 6: Novartis AG: Annual Financial Ratios
Table 7: Novartis AG: Annual Financial Ratios (Continued)
Table 8: Novartis AG: Key Employees
Table 9: Novartis AG: Key Employees Continued
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: Annual Financial Ratios
Table 12: Sanofi SA: Key Employees
Table 13: Sanofi SA: Key Employees Continued
Table 14: F. Hoffmann-La Roche Ltd: key facts
Table 15: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 16: F. Hoffmann-La Roche Ltd: Key Employees
Table 17: Pfizer Inc.: key facts
Table 18: Pfizer Inc.: Annual Financial Ratios
Table 19: Pfizer Inc.: Key Employees
Table 20: Pfizer Inc.: Key Employees Continued
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2015-19
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2019
Table 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2019-24
Table 4: Scandinavia pharmaceuticals market share: % share, by value, 2019
Table 5: Novartis AG: key facts
Table 6: Novartis AG: Annual Financial Ratios
Table 7: Novartis AG: Annual Financial Ratios (Continued)
Table 8: Novartis AG: Key Employees
Table 9: Novartis AG: Key Employees Continued
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: Annual Financial Ratios
Table 12: Sanofi SA: Key Employees
Table 13: Sanofi SA: Key Employees Continued
Table 14: F. Hoffmann-La Roche Ltd: key facts
Table 15: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 16: F. Hoffmann-La Roche Ltd: Key Employees
Table 17: Pfizer Inc.: key facts
Table 18: Pfizer Inc.: Annual Financial Ratios
Table 19: Pfizer Inc.: Key Employees
Table 20: Pfizer Inc.: Key Employees Continued
LIST OF FIGURES
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2015-19
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2019-24
Figure 4: Forces driving competition in the pharmaceuticals market in Scandinavia, 2019
Figure 5: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2019
Figure 6: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2019
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2019
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2019
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2019
Figure 10: Scandinavia pharmaceuticals market share: % share, by value, 2019
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2015-19
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2019-24
Figure 4: Forces driving competition in the pharmaceuticals market in Scandinavia, 2019
Figure 5: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2019
Figure 6: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2019
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2019
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2019
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2019
Figure 10: Scandinavia pharmaceuticals market share: % share, by value, 2019
